AIMS: Lipopolysaccharide (LPS) is a TLR4 agonist which activates NFκB dependent cytokine production. We investigated LPS inhalation in healthy smokers as a model of COPD bacterial exacerbations. We studied safety, reproducibility, the translocation of the NFκB subunit p65 in sputum cells and changes in systemic biomarkers of inflammation. METHODS: Twelve smokers inhaled 5 and 30 µg LPS and safety was monitored over 24 h. IL-6, CRP, CCl-18, SP-D, CC-16 and β-defensin 2 were measured in serum samples collected at baseline, 4, 8 and 24 h. Sputum was induced at baseline, 6 and 24 h for cell counts and p65 expression. Repeated challenges were performed after a 2 week interval in 10 smokers. RESULTS: LPS inhalation was well tolerated. Significant increases occurred in sputum neutrophil counts with both doses, with a maximum increase of 21.5% at 6 h after 30 µg which was reproducible, r(i ) (intraclass correlation coefficient) = 0.88. LPS increased sputum cell nuclear p65 translocation and phospho-p65 expression. All of the serum biomarkers increased following challenge but with different temporal patterns. DISCUSSION: Inhaled LPS challenge in smokers causes pulmonary and systemic inflammation that involves NFκB activation. This appears to be a suitable model for studying bacterial exacerbations of COPD.
AIMS: Lipopolysaccharide (LPS) is a TLR4 agonist which activates NFκB dependent cytokine production. We investigated LPS inhalation in healthy smokers as a model of COPD bacterial exacerbations. We studied safety, reproducibility, the translocation of the NFκB subunit p65 in sputum cells and changes in systemic biomarkers of inflammation. METHODS: Twelve smokers inhaled 5 and 30 µg LPS and safety was monitored over 24 h. IL-6, CRP, CCl-18, SP-D, CC-16 and β-defensin 2 were measured in serum samples collected at baseline, 4, 8 and 24 h. Sputum was induced at baseline, 6 and 24 h for cell counts and p65 expression. Repeated challenges were performed after a 2 week interval in 10 smokers. RESULTS: LPS inhalation was well tolerated. Significant increases occurred in sputum neutrophil counts with both doses, with a maximum increase of 21.5% at 6 h after 30 µg which was reproducible, r(i ) (intraclass correlation coefficient) = 0.88. LPS increased sputum cell nuclear p65 translocation and phospho-p65 expression. All of the serum biomarkers increased following challenge but with different temporal patterns. DISCUSSION: Inhaled LPS challenge in smokers causes pulmonary and systemic inflammation that involves NFκB activation. This appears to be a suitable model for studying bacterial exacerbations of COPD.
Authors: E Pizzichini; M M Pizzichini; A Efthimiadis; S Evans; M M Morris; D Squillace; G J Gleich; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1996-08 Impact factor: 21.405
Authors: Sergei P Atamas; Irina G Luzina; Jung Choi; Natalya Tsymbalyuk; Nicholas H Carbonetti; Ishwar S Singh; Maria Trojanowska; Sergio A Jimenez; Barbara White Journal: Am J Respir Cell Mol Biol Date: 2003-06-12 Impact factor: 6.914
Authors: Dorina Gabriela Karottki; Michal Spilak; Marie Frederiksen; Zorana Jovanovic Andersen; Anne Mette Madsen; Matthias Ketzel; Andreas Massling; Lars Gunnarsen; Peter Møller; Steffen Loft Journal: Int J Environ Res Public Health Date: 2015-02-02 Impact factor: 3.390
Authors: Naimish R Patel; Danen M Cunoosamy; Malin Fagerås; Ziad Taib; Sara Asimus; Tove Hegelund-Myrbäck; Sofia Lundin; Katerina Pardali; Nisha Kurian; Eva Ersdal; Cecilia Kristensson; Katarina Korsback; Robert Palmér; Mary N Brown; Steven Greenaway; Leonard Siew; Graham W Clarke; Stephen I Rennard; Barry J Make; Robert A Wise; Paul Jansson Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-03-27
Authors: Johann Bartko; Leopold Stiebellehner; Ulla Derhaschnig; Christian Schoergenhofer; Michael Schwameis; Helmut Prosch; Bernd Jilma Journal: Br J Clin Pharmacol Date: 2016-01-15 Impact factor: 4.335